NO144568C - Analogifremgangsmaate til fremstilling av 3-substituerte 4-fenylpiperidiner - Google Patents

Analogifremgangsmaate til fremstilling av 3-substituerte 4-fenylpiperidiner

Info

Publication number
NO144568C
NO144568C NO740272A NO740272A NO144568C NO 144568 C NO144568 C NO 144568C NO 740272 A NO740272 A NO 740272A NO 740272 A NO740272 A NO 740272A NO 144568 C NO144568 C NO 144568C
Authority
NO
Norway
Prior art keywords
substituted
preparation
analogy procedure
phenyl piperidines
piperidines
Prior art date
Application number
NO740272A
Other languages
English (en)
Norwegian (no)
Other versions
NO740272L (no
NO144568B (no
Inventor
Joergen Anders Christensen
Richard Felt Squires
Original Assignee
Ferrosan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9778288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO144568(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrosan As filed Critical Ferrosan As
Publication of NO740272L publication Critical patent/NO740272L/no
Publication of NO144568B publication Critical patent/NO144568B/no
Publication of NO144568C publication Critical patent/NO144568C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO740272A 1973-01-30 1974-01-29 Analogifremgangsmaate til fremstilling av 3-substituerte 4-fenylpiperidiner NO144568C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Publications (3)

Publication Number Publication Date
NO740272L NO740272L (no) 1974-07-31
NO144568B NO144568B (no) 1981-06-15
NO144568C true NO144568C (no) 1981-09-23

Family

ID=9778288

Family Applications (1)

Application Number Title Priority Date Filing Date
NO740272A NO144568C (no) 1973-01-30 1974-01-29 Analogifremgangsmaate til fremstilling av 3-substituerte 4-fenylpiperidiner

Country Status (20)

Country Link
US (2) US3912743A (de)
JP (2) JPS5946216B2 (de)
AT (1) AT333759B (de)
BE (1) BE810310A (de)
CA (1) CA1038390A (de)
CH (1) CH592059A5 (de)
DE (1) DE2404113C2 (de)
DK (1) DK149843C (de)
ES (2) ES422734A1 (de)
FI (1) FI57932C (de)
FR (1) FR2215233B1 (de)
GB (1) GB1422263A (de)
HK (1) HK13081A (de)
IE (1) IE38801B1 (de)
IT (1) IT1054157B (de)
LU (2) LU69264A1 (de)
NL (2) NL179187C (de)
NO (1) NO144568C (de)
PH (1) PH10383A (de)
SE (1) SE401827B (de)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800378A (en) * 1972-06-07 1974-04-02 Rca Corp Method of making a directly-heated cathode
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
DK149624C (da) * 1983-03-07 1987-02-02 Ferrosan As Fremgangsmaade til fremstilling af (+)-trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidin eller et farmaceutisk acceptabelt salt heraf ud fra en blanding af enantiomererne
US4593036A (en) * 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (de) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidinderivate mit gastro-intestinaler Wirkung
EP0223334B1 (de) * 1985-08-10 1991-07-10 Beecham Group Plc Verfahren zur Herstellung von Arylpiperidincarbinol
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
NO158038C (no) * 1985-10-21 1988-06-29 Standard Tel Kabelfab As Kabel.
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK588289D0 (da) * 1989-11-22 1989-11-22 Ferrosan As Ny heterocyklisk kemi
DK640289D0 (da) * 1989-12-18 1989-12-18 Ferrosan As Ny heterocyklisk kemi
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
DE4112353A1 (de) * 1991-04-16 1992-10-22 Basf Ag 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
EP0639568A1 (de) * 1993-08-19 1995-02-22 Novo Nordisk A/S Piperinderivate, ihre Herstellung und ihre Verwendung zur Behandlung von neurodegenerativen Krankenheiten
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
ES2102295B1 (es) * 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
JPH11505229A (ja) * 1995-05-17 1999-05-18 ノボ ノルディスク アクティーゼルスカブ ４−アリール−ピペリジン誘導体を製造する方法
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ATE192042T1 (de) * 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
ES2121685B1 (es) * 1996-04-10 1999-09-16 Vita Invest Sa Procedimiento para la obtencion de (+)-trans-4(4-fluoro-fenil)-3-hidroximetil-1-metilpiperidina.
JP3446468B2 (ja) 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (de) 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Verfahren zur Trocknung von Paroxetinhydrochlorid
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
GB9623359D0 (en) * 1996-11-09 1997-01-08 Smithkline Beecham Plc Novel process
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
ATE433959T1 (de) 1997-04-07 2009-07-15 Univ Georgetown Analoge von kokain
GB9710004D0 (en) * 1997-05-17 1997-07-09 Knoll Ag Chemical process
PL337513A1 (en) * 1997-05-29 2000-08-28 Smithkline Beecham Corp Novel method of obtaining pharmaceutically active compounds and their associated intermediate products
DE69704679T2 (de) 1997-06-10 2001-09-13 Synthon Bv 4-phenylpiperidin-derivate
CN1092654C (zh) * 1997-06-10 2002-10-16 斯索恩有限公司 4－苯基哌啶类化合物
CA2212451C (en) * 1997-08-07 2001-10-02 Brantford Chemicals Inc. Stereoselective and useful preparation of 3-substituted 4-aryl piperidine compounds
ES2137131B1 (es) * 1998-02-06 2000-09-16 Vita Invest Sa Derivado de piperidinona procedimiento de obtencion y procedimiento para su utilizacion.
SK13622000A3 (sk) * 1998-03-16 2001-03-12 Smithkline Beecham Plc Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
PL343378A1 (en) * 1998-04-09 2001-08-13 Smithkline Beecham Plc Paroxetine maleate
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
EP0969002B1 (de) 1998-06-29 2003-08-27 SUMIKA FINE CHEMICALS Co., Ltd. L-Tartrate von Trans-(-)-4-(4-Fluorphenyl)-3-Hydroxymethyl-Piperidin Verbindungen und Verfahren zu ihrer Herstellung
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
ATE239016T1 (de) * 1998-08-07 2003-05-15 Smithkline Beecham Plc Verfahren zur herstellung von einer nicht- kristallinen wasswerfreien form von paroxetin hydrochlorid
WO2000020390A1 (en) * 1998-10-07 2000-04-13 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
ES2211232T3 (es) * 1998-11-30 2004-07-01 Smithkline Beecham Plc Solvatos mixtos de paroxetina-propan-2-ol.
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
HUP0104036A3 (en) * 1998-12-22 2003-04-28 Pentech Pharmaceuticals Inc Bu Process for preparing arylpiperidine carbinol intermediates and derivatives
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9915303D0 (en) * 1999-06-30 1999-09-01 Smithkline Beecham Plc Novel process
BR0006838A (pt) * 1999-07-01 2001-08-07 Italfarmaco Spa Complexos de paroxetina, com ciclodextrinas ou derivados de ciclodextrinas
GB9915727D0 (en) * 1999-07-03 1999-09-08 Smithkline Beecham Plc Novel compound and process
GB9916187D0 (en) * 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
IT1313702B1 (it) 1999-08-02 2002-09-09 Chemi Spa Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9924882D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel process
GB9924855D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel processes
WO2001029002A1 (en) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Process for the preparation of 4-(fluorophenyl)piperidine esters
US6503927B1 (en) 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
AU2000246280A1 (en) 2000-05-12 2001-11-20 Synthon B.V. Tosylate salts of 4-(p-fluorophenyl)-piperidine-3-carbinols
US6833458B2 (en) 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
JP2004504319A (ja) * 2000-07-17 2004-02-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー ４−フェニルピペリジン誘導体の新規製造方法
GB0021145D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
GB0021147D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
WO2002028834A1 (en) * 2000-10-06 2002-04-11 Smithkline Beecham P.L.C. Process for the preparation of aryl-piperidine carbinols and intermediates thereof
AU2001210390A1 (en) * 2000-10-20 2002-04-29 Smithkline Beecham Plc Process of the preparation of 3-substituted-4-aryl piperidine compounds
EP1347960B1 (de) * 2001-01-04 2004-11-17 Ferrer Internacional, S.A. Verfahren zur herstellung von (+)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidin
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
WO2002068416A2 (en) * 2001-02-24 2002-09-06 Spurcourt Limited Process of preparing paroxetine and intermediates for use therein
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
US6930186B2 (en) * 2001-06-13 2005-08-16 Teva Pharmacetical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
WO2003020717A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
CN1606554B (zh) * 2001-10-12 2013-03-20 阿泽范药品公司 β-内酰胺后叶加压素V1a拮抗剂
WO2003044012A1 (en) * 2001-10-22 2003-05-30 Synthon B.V. N-formyl derivatives of paroxetine
US7396542B2 (en) * 2001-12-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US6956121B2 (en) 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
US7138523B2 (en) * 2002-05-16 2006-11-21 Apotex Pharmachem Inc. Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters
KR100477048B1 (ko) * 2002-07-05 2005-03-17 임광민 피페리딘 화합물의 새로운 제조방법
CA2502704A1 (en) * 2002-11-01 2004-05-13 Neurosearch A/S Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2004043921A1 (en) * 2002-11-11 2004-05-27 Natco Pharma Limited Novel process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines.
NZ577031A (en) 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
WO2005040169A2 (en) * 2003-09-17 2005-05-06 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as serotonin receptor modulators
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4864719B2 (ja) * 2003-11-26 2012-02-01 ファイザー・プロダクツ・インク Ｇｓｋ−３インヒビターとしてのアミノピラゾール誘導体
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
MX2007012936A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
WO2006116151A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
US20060264637A1 (en) * 2005-05-16 2006-11-23 Thippannachar Vijayavitthal M Preparation of paroxetine hydrochloride hemihydrate
EP1904843A2 (de) * 2005-07-08 2008-04-02 Braincells, Inc. Verfahren zur identifizierung von mitteln und zuständen für neurogenese-modulation
KR101521405B1 (ko) * 2005-07-19 2015-05-18 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신 길항물질
AU2006275595B2 (en) * 2005-07-29 2012-08-16 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
WO2007054896A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
EP1956906A4 (de) 2005-11-09 2009-12-30 Combinatorx Inc Verfahren, zusammensetzungen und kits für die behandlung von medizinischen beschwerden
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
JP5647519B2 (ja) * 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
EP2288345B1 (de) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psychopharmazeutika
BRPI0914891A2 (pt) * 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
WO2010056938A1 (en) 2008-11-14 2010-05-20 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2483281B1 (de) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituierte tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidinsalze
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CA2802541A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2587919B1 (de) 2010-07-01 2017-12-13 Azevan Pharmaceuticals, Inc. Verfahren zur behandlung posttraumatischer belastungsstörungen
BR112013023810A2 (pt) 2011-03-17 2016-12-13 Lupin Ltd composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
JP6055784B2 (ja) 2012-01-31 2016-12-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 パロキセチン誘導体
EP3122743B1 (de) 2014-03-28 2022-11-09 Azevan Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
IL273228B2 (en) 2017-09-15 2025-04-01 Azevan Pharmaceuticals Inc Preparations and methods for treating brain injury
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US20250042855A1 (en) * 2021-12-02 2025-02-06 The Johns Hopkins University Peripherally and luminally-restricted inhibitors of the serotonin transporter as treatments for disorders of gastrointestinal motility and gut-brain axis
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
GB2636182A (en) 2023-12-04 2025-06-11 Novumgen Ltd An orally disintegrating tablet of paroxetine and its process of preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976291A (en) * 1961-03-21 Ethers of z
US3178438A (en) * 1963-02-06 1965-04-13 Sterling Drug Inc 2-benzyl-3-hydroxy and lower alkoxy piperidines

Also Published As

Publication number Publication date
US3912743A (en) 1975-10-14
AT333759B (de) 1976-12-10
DE2404113C2 (de) 1985-07-11
DK149843B (da) 1986-10-13
US4007196A (en) 1977-02-08
NL7401189A (de) 1974-08-01
ATA69674A (de) 1976-04-15
SE401827B (sv) 1978-05-29
LU88398I2 (fr) 1994-05-04
LU69264A1 (de) 1974-04-10
NL179187C (nl) 1986-08-01
NO740272L (no) 1974-07-31
BE810310A (fr) 1974-05-16
JPS49101385A (de) 1974-09-25
JPS5948826B2 (ja) 1984-11-29
DK149843C (da) 1987-06-15
IE38801L (en) 1974-07-30
NO144568B (no) 1981-06-15
IT1054157B (it) 1981-11-10
CA1038390A (en) 1978-09-12
IE38801B1 (en) 1978-06-07
GB1422263A (en) 1976-01-21
NL930003I2 (nl) 1994-03-01
FR2215233A1 (de) 1974-08-23
ES556013A0 (es) 1987-07-16
JPS5946216B2 (ja) 1984-11-10
PH10383A (en) 1977-03-02
HK13081A (en) 1981-04-10
DE2404113A1 (de) 1974-08-08
FI57932C (fi) 1980-11-10
JPS58174363A (ja) 1983-10-13
ES422734A1 (es) 1976-04-01
CH592059A5 (de) 1977-10-14
NL179187B (nl) 1986-03-03
FR2215233B1 (de) 1977-01-28
FI57932B (fi) 1980-07-31
ES8707224A3 (es) 1987-07-16

Similar Documents

Publication Publication Date Title
NO144568C (no) Analogifremgangsmaate til fremstilling av 3-substituerte 4-fenylpiperidiner
SE7505040L (sv) Forfarande for framstellning av n-fosfonometylglycin.
NO145273C (no) N-formyl-alfa-l-aspartyl-l-fenylalanin for anvendelse til fremstilling av alfa-l-aspartyl-l-fenylalaninalkylestere
NO142401C (no) Analogifremgangsmaate til fremstilling av mavesyresekresjonshemmende 2-pyridylalkyltiobenzimidazoler
SE7710599L (sv) Forfarande for framstellning av bensisoxazoler
SE411212B (sv) Forfarande for framstellning av 3-halogen-cefalosporiner
SE421209B (sv) Analogiforfarande for framstellning av tienobensodiazepiner
NO142628C (no) Fremgangsmaate for fremstilling av polylaktoner
SE7506160L (sv) Forfarande for framstellning av n-cykloalkylmetyldekahydroisokinoline
NO141649C (no) Analogifremgangsmaate for fremstilling av neuroleptisk aktive 7-fluorsubstituerte fenotiaziner
SE415834B (sv) Analogiforfarande for framstellning av pyrazolderivat
NO843825L (no) Fremgangsmaate for fremstilling av 6-deoksytetracyklin
NO143625C (no) Analogifremgangsmaate for fremstilling av 2-metoksy-benzamider
SE411453B (sv) Forfarande for framstellning av 3-fluorcefalosporiner
SE417319B (sv) Analogiforfarande for framstellning av ergopeptiner
SE420089B (sv) Analogiforfarande for framstellning av fenoxipropylaminderivat (acetofenoner)
SE425248B (sv) Forfarande for framstellning ac derivat av 4-tia-2,6-diaza(3.2.0)-2-hepten-oner
SE411211B (sv) Forfarande for framstellning av 3-halogencefalosporiner
SE7511801L (sv) Forfarande for framstellning av ympsampolymerisat
SE394889B (sv) Forfarande for framstellning av tert butyl-4-tert butylperbensoat
SE401506B (sv) Forfarande for framstellning av bifenylyletrar
SE406086B (sv) Forfarande for framstellning av cyklisk-dikarboximido-substituerade fosfonotioater
SE7504507L (sv) Forfarande for framstellning av 5-nitroimidazolderivat.
SE7507482L (sv) Forfarande for framstellning av substituerade l-sulfonylbensimidazoler.
SE423627B (sv) Forfarande for framstelning av difenylbutylpiperidiner